查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612920

腦性腎上腺腦白質營養不良市場：按類型、最終用戶分類 - 全球預測 2025-2030

Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

腦性腎上腺腦白質營養不良市場2023年估值為53.6億美元，預計到2024年將達到59.5億美元，複合年成長率為11.21%，預計到2030年將達到112.9億美元。

腦性腎上腺腦白質營養不良 (CALD) 是一種嚴重的神經退化遺傳疾病，主要影響年輕男孩，是由 ABCD1 基因突變引起的，該突變會導致極長鏈脂肪酸在大腦中積聚。現有的治療方法有限，主要是實驗性治療，例如骨髓移植和 Eli-Cel 等基因治療。主要應用在醫療保健和製藥領域，它可以精確定位改變病程的創新療法。最終用途範圍主要包括醫療保健提供者、專科醫療中心和病患支援組織。潛在的成長要素包括個人化醫療的進步、增加基因篩檢以促進早期診斷以及增加對生物技術的投資。市場受到這些因素的影響，以及意識和宣傳的增加。最新的商機在於基因治療和CRISPR研究的擴展，鼓勵生技公司和學術機構之間的合作，以加速新療法的開發。研究指出，利用人工智慧主導的基因編輯來提高治療準確性，並專注於神經保護和再生的開創性研究。然而，關鍵的發展包括治療開發的高成本和複雜性、嚴格的法律規範以及疾病的稀有性，這抑制了臨床試驗的患者招募。圍繞基因治療的倫理問題也是一個問題。開發工作應包括整合奈米技術用於靶向藥物傳輸以及開發強大的臨床試驗基礎設施以加快治療方法的核准。該市場仍然是利基市場，其特點是大量的研發投資以及製藥公司之間的合作，以滿足未滿足的醫療需求。隨著監管環境逐漸變得更有利於孤兒藥指定，成功的參與者將從中受益，從而獎勵CALD 治療的投資。加強對疾病機制的研究和對家庭層面社會經濟影響的量化可能會進一步幫助行動者實施有意義的干涉措施。

主要市場統計
基準年[2023] 53.6億美元
預計年份 [2024] 59.5億美元
預測年份 [2030] 112.9億美元
複合年成長率（%） 11.21%

市場動態：快速發展的腦性腎上腺腦白質營養不良市場的關鍵市場洞察

供需的動態交互作用正在改變腦性腎上腺腦白質營養不良市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • CALD 的盛行率和診斷率不斷提高
    • 擴大醫療保健支出和保險覆蓋範圍
  • 市場限制因素
    • 治療成本上升和可近性問題
  • 市場機會
    • 治療產品開發的進展
    • 改善基因治療以達到精準治療
  • 市場挑戰
    • 腦性腎上腺腦白質營養不良治療產品開發與製造的複雜性

波特的五力：駕馭腦性腎上腺腦白質營養不良市場的策略工具

波特的五力框架是了解腦性腎上腺腦白質營養不良市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腦性腎上腺腦白質營養不良市場的外部影響

外部宏觀環境因素在塑造腦腎上腺腦白質營養不良市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析了解腦腎上腺腦白質營養不良市場的競爭格局

腦性腎上腺腦白質營養不良市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣腦性腎上腺腦白質營養不良市場供應商的績效評估

FPNV 定位矩陣是評估腦腎上腺腦白質營養不良市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製腦性腎上腺腦白質營養不良市場的成功之路

對腦性腎上腺腦白質營養不良市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • CALD 的盛行率和診斷率不斷提高
      • 擴大醫療費用和保險範圍
    • 抑制因素
      • 高治療成本和進入問題
    • 機會
      • 藥物開發的進展
      • 改善基因治療以達到精準治療
    • 任務
      • 腦性腎上腺腦白質營養不良治療產品開發與製造的複雜性
  • 市場區隔分析
    • 類型：基因檢測的持續創新加速腦性腎上腺腦白質營養不良的診斷
    • 最終使用者：專科診所在持續管理和專業治療中發揮重要作用。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腦性腎上腺腦白質營養不良市場：依類型

  • 診斷
    • 驗血
    • 基因檢測
    • MRI
    • 神經學檢查
  • 治療
    • 腎上腺荷爾蒙補充療法
    • 基因治療
    • 幹細胞移植

第7章腦性腎上腺腦白質營養不良市場：依最終用戶

  • 居家照護服務
  • 醫院和臨床
  • 專科診所

第8章北美及南美腦性腎上腺腦白質營養不良市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區腦性腎上腺腦白質營養不良市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲腦性腎上腺腦白質營養不良市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Neurocode 推出 ALZpath Dx 血液檢測，這是阿茲海默症診斷的突破
    • InSilicoTrials Technologies 與 Axoltis Pharma 之間的策略聯盟加強中樞神經系統藥物開發
    • FDA核准Lerigtazone 治療腦性腎上腺腦白質營養不良的 3 期 CALYX 研究
  • 戰略分析和建議

公司名單

  • bluebird bio, Inc.
  • Boston Scientific Corporation
  • Esaote SpA
  • FUJIFILM Corporation
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips NV
  • Medtronic PLC
  • MINORYX THERAPEUTIS SL
  • NeuroVia, Inc.
  • Neusoft Corporation
  • POXEL SA
  • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
  • Shimadzu Corporation
  • Siemens AG
  • Stryker Corporation
  • Toshiba Corporation
Product Code: MRR-CD5A9334D6B7

The Cerebral Adrenoleukodystrophy Market was valued at USD 5.36 billion in 2023, expected to reach USD 5.95 billion in 2024, and is projected to grow at a CAGR of 11.21%, to USD 11.29 billion by 2030.

Cerebral Adrenoleukodystrophy (CALD) is a severe neurodegenerative genetic disorder primarily affecting young boys, caused by mutations in the ABCD1 gene leading to the accumulation of very-long-chain fatty acids in the brain. The necessity for market presence stems from the urgent medical need for effective treatments, as existing options are limited and primarily involve bone marrow transplants or experimental therapies like gene therapy, such as Eli-Cel. The primary application is in the healthcare and pharmaceutical sectors, pinpointing innovative treatments to alter disease progression. End-use scope primarily involves healthcare providers, specialized medical centers, and patient support organizations. Potential growth factors include advancements in personalized medicine, increased genetic screening facilitating early diagnosis, and growing investments in biotechnology. The market is influenced by these factors alongside rising awareness and advocacy initiatives. The latest opportunities lie in the expansion of gene therapy and CRISPR research, encouraging collaborations between biotech firms and academic institutions to accelerate novel therapeutic developments. Recommendations point towards a focus on pioneering research in neural protection and regeneration, leveraging AI-driven gene editing to enhance therapeutic precision. However, key limitations include the high cost and complexity of treatment development, stringent regulatory frameworks, and the rarity of the disorder which curtails patient recruitment for clinical trials. Challenges also involve navigating ethical concerns surrounding genetic treatments. Innovations should explore integrating nanotechnology for targeted drug delivery and developing robust clinical trial infrastructures to expedite therapy approvals. The market remains niche, characterized by significant R&D investment and collaboration among pharmaceutical companies to address unmet medical needs. Successful players will likely benefit from a regulatory landscape that gradually favors orphan drug designations, creating incentives for investment in CALD treatments. Enhanced research into the disease mechanism and quantification of socio-economic impacts on familial units may further position entities at the helm of meaningful interventions.

KEY MARKET STATISTICS
Base Year [2023] USD 5.36 billion
Estimated Year [2024] USD 5.95 billion
Forecast Year [2030] USD 11.29 billion
CAGR (%) 11.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cerebral Adrenoleukodystrophy Market

The Cerebral Adrenoleukodystrophy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased prevalence and diagnostic rates of CALD
    • Growing healthcare expenditure and insurance coverage
  • Market Restraints
    • High cost of treatment and accessibility issues
  • Market Opportunities
    • Advancements in therapeutic product development
    • Improvements in gene therapy for precision treatment
  • Market Challenges
    • Product development and manufacturing complexities in cerebral adrenoleukodystrophy treatment

Porter's Five Forces: A Strategic Tool for Navigating the Cerebral Adrenoleukodystrophy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cerebral Adrenoleukodystrophy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cerebral Adrenoleukodystrophy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cerebral Adrenoleukodystrophy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cerebral Adrenoleukodystrophy Market

A detailed market share analysis in the Cerebral Adrenoleukodystrophy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cerebral Adrenoleukodystrophy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cerebral Adrenoleukodystrophy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cerebral Adrenoleukodystrophy Market

A strategic analysis of the Cerebral Adrenoleukodystrophy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cerebral Adrenoleukodystrophy Market, highlighting leading vendors and their innovative profiles. These include bluebird bio, Inc., Boston Scientific Corporation, Esaote S.p.A, FUJIFILM Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic PLC, MINORYX THERAPEUTIS SL, NeuroVia, Inc., Neusoft Corporation, POXEL SA, SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD., Shimadzu Corporation, Siemens AG, Stryker Corporation, and Toshiba Corporation.

Market Segmentation & Coverage

This research report categorizes the Cerebral Adrenoleukodystrophy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diagnosis and Treatment. The Diagnosis is further studied across Blood Tests, Genetic Testing, MRI, and Neurological Tests. The Treatment is further studied across Adrenal Hormone Replacement, Gene Therapy, and Stem Cell Transplantation.
  • Based on End-User, market is studied across Home Care Services, Hospitals & Clinical, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased prevalence and diagnostic rates of CALD
      • 5.1.1.2. Growing healthcare expenditure and insurance coverage
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and accessibility issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapeutic product development
      • 5.1.3.2. Improvements in gene therapy for precision treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Product development and manufacturing complexities in cerebral adrenoleukodystrophy treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Ongoing innovations in genetic testing to accelerate the diagnosis of cerebral adrenoleukodystrophy
    • 5.2.2. End-User: Specialty clinics play a significant role in ongoing management and specialized treatments.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cerebral Adrenoleukodystrophy Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.2.1. Blood Tests
    • 6.2.2. Genetic Testing
    • 6.2.3. MRI
    • 6.2.4. Neurological Tests
  • 6.3. Treatment
    • 6.3.1. Adrenal Hormone Replacement
    • 6.3.2. Gene Therapy
    • 6.3.3. Stem Cell Transplantation

7. Cerebral Adrenoleukodystrophy Market, by End-User

  • 7.1. Introduction
  • 7.2. Home Care Services
  • 7.3. Hospitals & Clinical
  • 7.4. Specialty Clinics

8. Americas Cerebral Adrenoleukodystrophy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cerebral Adrenoleukodystrophy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cerebral Adrenoleukodystrophy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Breakthrough in Alzheimer's Disease Diagnosis as Neurocode Launch ALZpath Dx Blood Test
    • 11.3.2. Strategic Collaboration between InSilicoTrials Technologies and Axoltis Pharma to Enhance CNS Drug Development
    • 11.3.3. FDA Approves Phase 3 CALYX Trial for Leriglitazone in Treatment of Cerebral Adrenoleukodystrophy
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. bluebird bio, Inc.
  • 2. Boston Scientific Corporation
  • 3. Esaote S.p.A
  • 4. FUJIFILM Corporation
  • 5. GE HealthCare Technologies Inc.
  • 6. Koninklijke Philips N.V.
  • 7. Medtronic PLC
  • 8. MINORYX THERAPEUTIS SL
  • 9. NeuroVia, Inc.
  • 10. Neusoft Corporation
  • 11. POXEL SA
  • 12. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
  • 13. Shimadzu Corporation
  • 14. Siemens AG
  • 15. Stryker Corporation
  • 16. Toshiba Corporation

LIST OF FIGURES

  • FIGURE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET RESEARCH PROCESS
  • FIGURE 2. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CEREBRAL ADRENOLEUKODYSTROPHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CEREBRAL ADRENOLEUKODYSTROPHY MARKET DYNAMICS
  • TABLE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NEUROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADRENAL HORMONE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS & CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. CEREBRAL ADRENOLEUKODYSTROPHY MARKET, FPNV POSITIONING MATRIX, 2023